A pivotal, __number__ -week, randomized, double-blind, placebo-controlled, phase II study in children and adolescents in ten European countries demonstrated that the stimulant prodrug lisdexamfetamine dimesylate (LDX) is an effective and generally well-tolerated treatment for symptoms of ADHD.